Abstract-Anaphylaxis is an increasingly prevalent life-threatening allergic condition that requires people with anaphylaxis and their caregivers to be trained in the avoidance of allergen triggers and in the administration of adrenaline autoinjectors. The prompt and correct administration of autoinjectors in the event of an anaphylactic reaction is a significant challenge in the management of anaphylaxis. Unfortunately, many people do not know how to use autoinjectors and either fail to use them or fail to use them correctly. This is due in part to deficiencies in training and also to the lack of a system encouraging continuous practice with feedback. Assistive smartphone healthcare technologies have demonstrated potential to support the management of chronic conditions such as diabetes and cardiovascular disease, but there have been deficiencies in their evaluation and there has been a lack of application to anaphylaxis. This paper describes AllergiSense, a smartphone app and sensing system for anaphylaxis management, and presents the results of a randomized, controlled, prepost evaluation of AllergiSense injection training and feedback tools with healthy participants. Participants whose training was supplemented with AllergiSense injection feedback achieved significantly better practiced injections with 90.5% performing correct injections compared to only 28.6% in the paper-only control group. In addition, the results provide insights into possible self-efficacy Stiefel@uhl-tr.nhs.uk; kerrie.kirk@uhl-tr.nhs.uk 
I. INTRODUCTION
A NAPHYLAXIS is a serious allergic reaction that is rapid in onset and can cause death [1, p. 392] . Its prevalence has dramatically increased in recent years [2] with an estimated lifetime prevalence of 0.05-2% [3] - [5] . Anaphylactic reactions can occur rapidly after ingestion, inhalation or contact with an allergen that may be a food, prescription drug, insect sting, or a substance such as latex [6] . Foods are the most common allergens for children, adolescents, and young adults, while nonfood allergens are more common for older adults [7] . Children frequently develop tolerance to milk, egg, soy, and wheat allergens by school age; however, allergies to nuts and shellfish are more likely to be lifelong [8] .
The first-line treatment for an anaphylactic reaction is the immediate administration of adrenaline (epinephrine) given via a preloaded adrenaline autoinjector (AAI) into the outer thigh and an ambulance must be called [9] . If symptoms do not improve in 5-10 min, a second injection is advised [10] , [11] . Correct use of the most commonly prescribed AAI brands, EpiPen and Jext, requires the correct completion of four steps: 1) safety cap removal; 2) delivery to the thigh; 3) holding in place for 10 s; and 4) massaging the injection site for 10 s. Empty needleless AAI trainer devices are available for the purpose of practicing injections.
The management of anaphylaxis requires allergen avoidance and emergency preparedness [7] , [9] , [12] , [13] . Allergen avoidance includes the inspection of food ingredient labeling [12] , [14] , for example, a chocolate bar may have precautionary advisory labeling such as "may contain nuts," and awareness of contamination risks, for example, if food is cut with a knife that has been in contact with an allergen. Emergency preparedness includes knowing how to recognize anaphylaxis symptoms, training in the use of AAIs [15] and having an emergency allergy action plan [9] , [10] , [16] , [17] .
The contribution of this paper is threefold: 1) it presents AllergiSense, a prototype smartphone app and sensing system for emergency preparedness in anaphylaxis management; 2) it provides laboratory evidence, for an injection feedback tool, of significantly improved practice injection skills; and 3) it provides proof-of-concept evidence to support a case for future clinical trials implementing the technology with both physicians and patients inside and outside the clinic.
AllergiSense design and evaluation was motivated by the fact that the correct use of AAIs is significant in anaphylaxis management [18] and because there are widely reported failures in the provision of appropriate training and failures in AAI injection procedure [19] - [29] . For example, Brown et al. [20] reported that only 15 out of 100 mothers could correctly demonstrate AAI use despite a prior demonstration. Arkwright and Farragher [30] found that 69% of the parents of food allergic children attending a U.K. clinic were unable to use their AAIs, did not have them available or did not know when to administer them. In a randomized study with 343 previously trained Canadian school staff, Nguyen-Luu et al. [27] found that only 26.3% of the participants who had been fully informed at recruitment about the AAI assessment could demonstrate correct AAI use. And only 15.8% of the participants who were not fully informed about the assessment could correctly demonstrate AAI use. Physicians have also been shown to lack AAI skills [19] , [29] . For example, Mehr et al. [26] have suggested that insufficient knowledge from prescribing physicians was a contributing factor to the failure of parents and children activating the device correctly. The authors recruited 100 pediatric hospital physicians (including residents, registrars, and consultants), half of whom had already prescribed AAIs. Only 2% of their demonstrated injections were assessed as fully correct, improving to 41% after they reviewed AAI instructions but still one in five self-injected their own thumbs. Similarly, Arga et al. [19] found in a study with 151 general pediatrics physicians, residents, and consultants that only 35 (23%) were able to demonstrate correct AAI use, improving to 74% after training and practice. Observing deficiencies on retesting six months later, recommended repetition of education.
The consensus in the clinical literature is that training should be improved and should ensure correct injection techniques are used, and that training should be continuous, monitored, and assessed by allergy specialists so that skills are refreshed and maintained [9] , [19] , [25] , [26] , [28] , [31] , [32] .
Advances in pervasive and assistive health technology research, evident in the expanding literature, have contributed toward improved management of other chronic health conditions such as diabetes, asthma, cardiovascular diseases [33] - [35] , and mental illness [36] , but anaphylaxis has been neglected [37] . A search of online app stores (Android and Apple-August 2014) returned nine information-giving smartphone anaphylaxis apps and services, most of which were produced by support groups [38] and AAI manufacturers [39] , [40] . For example, there were apps with instructions for using a manufacturer's AAI, apps providing text reminder services about AAI expiry dates and apps providing text alerts about allergen contamination in the food supply chain. As with other healthcare apps, there is a lack of reported evaluation in the literature [41] , [42] . In addition, there are no systems or apps providing feedback on injection performance or encouraging maintenance of AAI skills.
We aimed to investigate whether adrenaline injection training using AllergiSense to supplement traditional paper documents could provide improved injection training skills and better selfefficacy levels in comparison with adrenaline injection training using paper documents alone. The following section presents the design of AllergiSense, and then, Section III describes its implementation. Section IV explains how AllergiSense injection feedback tools were evaluated and Section V presents the results of the evaluation. Finally, Section VI provides a discussion of results and Section VII outlines the conclusions of this paper.
II. ALLERGISENSE DESIGN

A. Design Based on Self-Efficacy Theory
The AllergiSense design and its evaluation were grounded in self-efficacy theory [43] . Self-efficacy theory is central to social cognitive theory. It refers to one's belief in one's ability and it is a major predictor of self-management outcomes and a contributor to performance ibid.
Self-efficacy is modified by four information sources [43] : Enactive experience-experiencing attainment through practice and mastery. Vicarious experience-modeling others. Social persuasion-encouragement or discouragement from others. Physiological states-interpretation of one's physiological responses as indicators of personal competency.
Health-promotion interventions based on social and behavioral science theories are more effective than those without a theoretical base [44] . Though technology evaluations may incorporate assessments of self-efficacy, the majority of reported studies are not theoretically based on such. In a review of mobile devices for healthcare and behavioral change, Free et al. [34] observed only seven of 26 (26.9%) behavioral change studies reported using behavioral change theories to underpin their intervention.
B. Design Methodology
The ambition of AllergiSense was to support anaphylaxis self-management. The design and evaluation was informed by technological prototyping [37] , [45] , participatory design [46] , and a multistage methodology enriched with embedded selfefficacy sources.
The motivation for incorporating participatory design was to evolve an improved design from a deeper understanding of anaphylaxis management needs and from different perspectives of users and stakeholders. The participatory design process, shown in Fig. 1 , comprised two workshop events with expert clinical participants, caregivers for individuals at risk of anaphylaxis, an adult with a history of anaphylaxis, and system designers. Participants identified two main anaphylaxis management contexts: emergency and everyday life. They also identified specific management needs including help to educate others, support for AAI use and AAI management, and help with emergency situations. Participants created paper interface prototypes of tools to support these needs using the PICTIVE (Plastic Interface for Collaborative Technology Initiatives through Video Exploration) participatory design approach [46] .
In addition to tools explicitly suggested in the participatory design process, an AAI injection training tool was created as a vehicle to increase self-efficacy: encouraging mastery (via performance support) and providing persuasion (via feedback). A simplified injection force-sensing tool had been developed in earlier technology prototyping [37] . The tool was enhanced and a new user interface was included in mock-ups presented at the participatory design session 2 for participant feedback. Interfaces for the full set of tools were mocked-up using Balsamiq software for higher fidelity user interface prototyping. Fig. 2(a) shows an example of one of the interface design choices presented to participants and Fig. 2(b) shows examples of participant preferences. As well as the bold and strictly consistent use of function coloring (red for emergency and green for everyday function), these examples demonstrate ways in which AllergiSense design considerations varied from those of a generic app. With effective and error-free use identified as a top priority, clarity, simplicity, and consistency were essential to the interface design. For example, of the choices shown in Fig. 2(a) , participants preferred the simple button menu style with sympathetic coloring. In Fig. 2(b) , participant annotations show a preference for the emergency button (and cancel emergency button) at the top of the screen which they said would improve visibility and better avoid pressing it by mistake, and, as shown, ticks and crosses were preferred for clarity in the injection training feedback tool.
III. ALLERGISENSE IMPLEMENTATION
A. AllergiSense Mobile Application Tools
The AllergiSense design and the information content were subject to clinical inspection prior to the production of the final prototype used in the evaluation. AllergiSense was implemented in an Android Smartphone. Example screenshots are shown in In part, this tool is equivalent to the alert services provided by these manufacturers which send email or SMS text messages at four months and two months prior to expiry and again one day after expiry. But, as suggested by our design participants, this AllergiSense tool has additional functionality, for example, it stores the usual location of each AAI and provides the number of days before each expires. Green, yellow, and red emoticons also summarize the AAI expiry states, namely, "OK," "nearing expiry," and "expired," respectively.
For emergency scenarios, AllergiSense tools include a singlescreen emergency "what to do" list and step-by-step AAI instructions. In addition, AllergiSense emergency messaging tools can send text messages to predefined numbers identifying the user's GPS location, and emergency services can be contacted with the touch of a button. Fig. 4 shows the sensing unit mounted on an AAI trainer device. It was encased in a slim plastic cover and comprised an Arduino "Pro mini" microcontroller, a three-axis accelerometer, a push button sensor (to detect removal of the safety cap), a Bluetooth transceiver, and a coin cell battery.
B. AllergiSense Sensing Unit
The role of the sensing unit was to detect removal of the safety cap and to collect acceleration data. The accelerometer sensor unit was configured to sample X, Y, and Z acceleration channels at 70 Hz. This sampling rate was empirically selected as sufficiently high for injection sensing fidelity and sufficiently sustainable in terms of battery life. All data were transmitted to the smartphone using a Serial Port Profile and used by the injection feedback training tool to determine if the safety cap had been removed, if the injector was held the right way around, if a "swing and jab" was performed and if the trainer was held in place for 10 s.
The removal of the safety cap was detected directly by the sensor underneath the cap. Two action classes were used to identify the injection steps: "swinging and jabbing" (when delivering the injection) and "still" (when holding the trainer injector in place). A third class, "moving," was defined as any other action. These classes were defined by accelerometer training data from 12 correctly performed injections provided by an allergy clinician. All the clinician's injections were performed with the right hand (the clinician's dominant hand). Six were performed while standing and six while sitting.
Classification was performed using a J48 binary decision tree using accelerometer data features that included the mean, standard deviation, maximum and minimum values, difference between the maximum and minimum values, and the average distance from the mean. J48 is an open-source Java implementation of the C4.5 decision tree algorithm in the WEKA data mining application. This algorithm was chosen for ease of implementation and its robust performance in testing. A correct injection is identified as a sequence of steps in the following order: "moving," "swinging and jabbing," "still," and "moving." The results of testing with participant data were: "swinging and jabbing" was classified with an accuracy of 81%, precision of 96%, and recall of 83% (F-measure = 89%); "still" was classified with an accuracy of 81%, precision of 83%, and recall of 91% (F-measure = 87%).
C. AllergiSense Injection Feedback Tool
The AllergiSense injection feedback tool provides out-of-six marks for practiced injections as depicted in Fig. 3(h) . The tool assesses injection site and massage time via two questions with randomly located answers in pull-down menus [shown in Fig. 3(g) ], and the other four assessments (cap removed, injector the right way around, swing and jab, and held in place for 10 s) are assessed automatically via the data communicated from the sensing unit.
If users provide incorrect responses or perform erroneous actions these are marked as incorrect as depicted in Fig. 3(h) , the out-of-six score is deducted accordingly and informative recommendations are provided in a subsequent screen if the user presses the 'Recommendations' button. The recommendation explains how to improve a specific step of the injection and encourages another injection training attempt.
IV. ALLERGISENSE EVALUATION
The AllergiSense adrenaline injection training tool was evaluated with a three-arm, prepost (two-week), randomized controlled study with 63 healthy participants recruited from the University of Birmingham, U.K.
The main hypothesis of this evaluation was that using AllergiSense (in addition to traditional training using information leaflets) would enhance adrenaline injection training skills compared to traditional instruction using information leaflets alone. The primary aim of the evaluation was an assessment of the effect of different training materials on practiced adrenaline injection skills. The secondary aim was to evaluate participants' self-reported AAI self-efficacy, workload, system usability, system usefulness, ease-of-use, and attitudes toward its use.
The training provided was clinically approved and the procedure overseen by an expert clinical collaborator.
A. Statistics
A Shapiro-Wilk test was used to test if results were samples of a normally distributed population (Significance level = 0.05) [47] . Parametric t-tests and ANOVA test were used on normally distributed results; Friedman's Rank and Mann-Whitney (U) tests for results not normally distributed and chi-squared test (χ 2 ) for comparing frequencies of data. The statistical tests were undertaken using SPSS version 20.
B. Participants
Sixty-three student and staff participants aged between 18 and 60 were recruited via email invitation from the University of Birmingham, U.K. All participants reported carrying and using mobile phones. Participants were block randomized into three groups of 21 participants. The groups comprised participants with broadly equivalent smartphone experience in terms of smartphone usage and number of apps used, and with similar average age and gender balance, and all participants were right-handed. Individuals known to be at risk of anaphylaxis and their caregivers were excluded from the study (their recruitment would have required extensive National Health Service ethical permissions; future approval for testing of new technology with patients would be more likely in the event of positive outcomes from testing with healthy participants).
C. Assessment of Performance and Administered Questionnaires
The assessment of AAI performance was based on the fourstep marking scheme used in other studies [19] , [29] , which, in turn, were based on the steps recommended by the EpiPen AAI manufacturer [48] , which are the following.
1) "Remove the blue safety cap.
2) "Swing and jab" the orange tip of the AAI trainer against the outer thigh until it "clicks." 3) Hold firmly against the thigh for 10 s. 4) Remove the autoinjector from the thigh. The orange tip will extend to cover the needle and massage the injection area for 10 s."
The AllergiSense system separates step 2 into two by 1) sensing "swing and jab" and 2) explicitly asking the user to select the correct injection site from a randomly ordered list. In addition, AllergiSense senses for the injector being held the right way around. This means that while AllergiSense assesses the four step injection performance, it reports on-screen out of six rather than out of four [see Fig. 3(h) ].
The performance of all participants' adrenaline injections was evaluated via video observation of the four recommended steps. An interrated test with an independent researcher was carried out with a random sample of injections (Cohen's Kappa > 0.8). Injection step differences were discussed with, and verified by, the independent researcher using the recorded video and sensor data from the AllergiSense sensing unit.
1) Workload and Self-Reported Usability: NASA TLX [49] and System Usability Scale (SUS) [50] questionnaires were used for evaluation of workload and self-reported usability, respectively. NASA TLX quantifies workload component levels of mental, physical, and temporal demands. The SUS questionnaire provides a measure of perceived usability, covering aspects of acceptance, need for support, training, and system complexity [51] , [52] .
2) Self-Efficacy: A self-efficacy questionnaire for adrenaline injection was created using eleven-point (0: Not at all confident, 10: Totally confident) scale responses as recommended by Bandura [53] . The questionnaire comprised statements relevant to the use of AAIs in training and emergencies for participants to rate. For example, "I am confident that I can correctly use an autoinjector trainer in a practice session," "I am confident I can apply the correct force when injecting," "I am confident I can identify the correct injection site," "I am confident I can correctly use an autoinjector in an allergic emergency," and "I am confident that I would inject correctly in an emergency even if I am very anxious." The selection and phrasing of the questions was first reviewed by allergy clinical collaborators and assessed by 18 allergy specialists.
3) Usefulness, Ease-of-Use, and Attitudes Toward Use: Self-reported measures of usefulness, ease-of-use, and willingness regarding use were collected from technology acceptance questionnaires [54] .
D. Materials
Subsequent to clinically approved training (i.e., allergy specialist's videos about anaphylaxis and EpiPen use), participants were randomly assigned to one of the three following groups.
1) Paper (Traditional Care Information With Paper Leaflets Documentation).:
Participants in all groups received a paper copy of the EpiPen AAI instruction leaflet (the instructions for use provided in the EpiPen AAI patient information). This document provides information about injector use and stepby-step pictures for each of the four injection steps. Participants in the paper-only (control) group received only this information. Participants in the other groups had this material supplemented with AllergiSense materials as described below.
2) AllergiSense Without Feedback: Participants in this group received the AllergiSense smartphone system without the injection practice feedback functionality, i.e., AllergiSense without the out-of-six injection practice feedback. Thus participants with AllergiSense without feedback were provided with the paper instructions (the same as the control paper group) supplemented with smartphone video (an instructional Epipen AAI video produced by the manufacturer and available online on the EpiPen AAI website) and an AAI step-by step instruction tool [text and pictures as per paper steps depicted in Fig. 3(f) ].
3) AllergiSense: This was the complete AllergiSense smartphone system using the sensing unit connected to the AllergiSense smartphone and providing out-of-six injection feedback. Thus, participants in this group were provided paper instructions (the same as the control paper group) supplemented with smartphone AAI step-by-step instructions [see Fig. 3(f) ] and an AAI usage video (the same as the AllergiSense without feedback) and the mark out-of-six injection feedback [see Fig. 3(h) ].
All three groups used the same AllergiSense sensing unit depicted in Fig. 4 . All sensor data for all participants in all groups were logged and recorded during the experimental sessions. Data from the paper-only group and the AllergiSense without feedback group were recorded via HyperTerminal for research records. The data of the AllergiSense group were recorded in the smartphone. Participants in the AllergiSense group were the only people that received feedback about their training injections.
E. Experimental Procedure
The experiment comprised two sessions, two weeks apart. In session 1, participants were randomly allocated to one of the three groups. All participants received the same clinically approved training with videos of an allergy specialist using an EpiPen AAI trainer. Participants were then asked to demonstrate an injection of adrenaline with the trainer device (Demonstration 1) and were then provided with one of three different training materials described earlier: paper-only, AllergiSense without feedback or AllergiSense. Participants were then required to practice three injections using their allocated training materials before completing a demonstration injection (Demonstration 2). In session 2, two weeks later, participants were recalled to demonstrate their injection skills (Demonstration 3) then practice three injections using their allocated training material before completing a final demonstration injection (Demonstration 4).
Only the participants in the AllergiSense group received feedback on their injection performance [from the injection feedback training tool; see Fig. 3(h) ]. All other participants received no feedback on their injections until they were provided with an account during the experimental debrief at the end of session 2. None of the participants reported extra training between sessions. Table I shows the number of participants in each group that correctly completed the four injection steps. Only 28.6% of the paper-only group correctly completed all four injection steps in their final demonstration versus 66.7% for AllergiSense without In contrast, the paper-only group actually deteriorated in session 2: from 8 to 6 of 21 participants injecting correctly, and across the four demonstrations, there was no significant change in this group's injection ability despite the training opportunities (p > 0.05).
V. RESULTS
For the two AllergiSense groups, the number of errors made decreased with training. The total number of injection errors from all four demonstrations of the three groups was 225 (from a theoretical maximum of 1008 errors = 63[participants] × 4[possible errors] × 4[demonstrations]). Only 3.1% of all errors involved a failure to remove the safety cap and all of these occurred in Demonstration 1. Not massaging the injection site for 10 s comprised 52.9% of all errors, not injecting with sufficient force comprised 24.9% and not holding the AAI trainer in place for 10 s comprised the remaining 19.1% of all errors.
In Demonstration 2, more participants in the paper-only group injected with sufficient force in comparison with the AllergiSense groups, but the difference was not significant (p > 0.05). However, at the end of the study (Demonstration 4), both AllergiSense groups made significantly less errors in this step than the paper-only group. More participants in both AllergiSense groups held the AAI trainer in place for 10 s in all four of their demonstrations, compared with the paper-only group. After training with their allocated material, in Demonstrations 2 and 4, more people in both AllergiSense groups massaged the injection site for 10 s and made significantly less errors in this step at the end of the two-week study in comparison with the paper-only group. Table II shows the questionnaire results for self-efficacy, usefulness, ease-of-use, attitudes toward use, system usability, and workload. Self-efficacy differences within groups were seen after training with their allocated material in session 1 (from Demonstration 1 to Demonstration 2). The self-efficacy of the paper-only group increased from 7.5 to 8.5 (p < 0.001), the AllergiSense without feedback group increased from 7.6 to 8.6 (p < 0.001), and the AllergiSense group increased from 7.1 to 8.5 (p < 0.001). Self-efficacy remained high for the three groups for two weeks, and no significant differences were found between the three groups (p > 0.05).
After using their allocated material in session 1 (after Demonstration 2), participants in both the AllergiSense and AllergiSense without feedback groups reported significantly higher average scores for the usefulness, the ease-of use, and in the willingness to use their training materials compared to the paperonly group as follows. Usefulness: 5.1 (paper) versus 6.1 (AllergiSense without feedback) (p = 0.012); 5.1 (paper) versus 6.1 (AllergiSense) (p = 0.001); Ease-of-use: 4.7 (paper) versus 6.2 (AllergiSense without feedback) (p = 0.001); 4.7 (paper) versus 6.0 (AllergiSense) (p = 0.005); Willingness toward use: 5.1 (paper) versus 6.1 (AllergiSense without feedback) (p < 0.001) and 5.1 (paper) versus 6.1 (AllergiSense) (p < 0.001). Differences between AllergiSense and AllergiSense without feedback were not statistically significant.
In addition, both AllergiSense groups reported significantly higher system usability scores (SUS), after Demonstration 2, than the paper-only group: 68.5 (paper) versus 86.3 (AllergiSense without feedback) (p < 0.001); 68.5 (paper) versus 82.7 (AllergiSense) (p = 0.001). While the workload, reported after Demonstration 4, was not significantly different between groups (p = 0.991).
VI. DISCUSSION OF RESULTS
While the results of small studies should, necessarily, be interpreted cautiously, the results presented here provide a measure of evidence toward the hypothesis that smartphone tools supplementing traditional instruction paper leaflets could improve adrenaline injection training skills.
The improved results for AllergiSense could be a consequence of improved training from the explicit and purposeful reinforcement of self-efficacy via mastery, vicarious, and social experiences embedded within videos, step-by-step instructions, and visual feedback. In contrast, paper instructions provide only limited modeling opportunities from text and pictures. There was no significant improvement in the performance of the paper-only group throughout the study.
The results appear to support other reports in the literature [19] - [29] regarding the inadequacy of the current approach to adrenaline injection education (i.e., expert explanation and AAI demonstration). Current instruction, where the use of AAIs is just demonstrated, does not include provision for feedback, nor encouragement nor support of continuous practice. This was observed after Demonstration 1 (after the clinically approved training) when, at best, only one-third of people in the three groups could correctly complete all four steps of the injection (23.8%, 19%, and 33.3% for control, AllergiSense without feedback, and AllergiSense, respectively). These very low results concur with other extremely poor findings reported in the literature.
One interesting and unexpected result was the significant increase in self-efficacy in the paper-only group after first use of their material for training (after Demonstration 2). This increase was less than the increase for the AllergiSense groups but not significantly so. The paper-only group retained their increased self-efficacy throughout the study despite the lack of any significant improvement in their performance. This was exemplified at the end of session 2 by one paper-only participant who had made no correct injection demonstrations at all, but expressed surprise for each when informed of the results. Bandura [55] has reported that improved self-efficacy in the absence of improved performance indicates a problem in the system. Perhaps then, the experiment revealed something of the problem with the current system, i.e., that in the absence of monitoring and feedback people have elevated self-efficacy based on incorrect assumptions about their mastery skills. This could have several consequences, not least the lack of motivation for continuous practice.
Secondary outcome results showed that participants reported no significant differences in workload for the three different training materials. Interestingly, compared to the paperonly group both AllergiSense groups scored significantly better for usefulness and ease-of-use of their materials and also reported significantly more willingness towards use. Additionally, average self-reported usability scores (SUS) for both AllergiSense groups were very positive. The paper-only participants reported, according to Bangor Results showed that adrenaline injection self-efficacy improved after the first training session and then was not significantly different two weeks later. Perhaps if participants had been recalled six weeks or six months later, these self-efficacy results might be substantially different. Further work involving longer term studies is recommended to investigate how selfefficacy and adrenaline injection skills attenuate over time and how these are impacted by the training materials used.
This research was limited to short-term evaluations with healthy participants. Thus, in every aspect of the work presented here, there is scope for further contribution. Children are most affected by anaphylaxis and the most common allergen, peanuts, is not generally outgrown. This new generation will need support in the management of their anaphylaxis. We hope that the results presented here will encourage further technology research and development in support of anaphylaxis management. For example, further work is also needed to populate solutions with content and define tools aimed at supporting symptom recognition and allergen avoidance. Further work could also consider the issues of responsibility for the support and maintenance of the technology and the information contained within it. In addition, further work is needed for the creation and validation of self-efficacy questionnaires for anaphylaxis management and adrenaline injection and, importantly, much further work is needed for evaluation of tools in longitudinal studies with patients in and outside the clinic.
VII. CONCLUSION
This paper provided experimental evidence supporting the potential of smartphone tools and wireless sensors to significantly improve AAI training skills, usefully supplement traditional care paper information leaflets and positively influence injection training performance and user's self-efficacy. The study was limited to a randomized, controlled, prepost intervention with healthy participants simulating adrenaline injections with an AAI trainer, but still the results provided valuable insights and proof-of-concept evidence to support a case for future clinical trials implementing the technology with both physicians and patients.
It was noted that participants in the control group, trained with traditional care paper information leaflets alone, did not improve their AAI performance and made persistent errors in administration of the AAI throughout training practice. Notwithstanding the poor AAI skills exhibited by the paper-only group, the results revealed that their levels of self-efficacy increased, despite being wholly incompatible with their actual AAI skills. While it is important to be cautious in the interpretation of these data given the limited participant numbers, this finding was interesting and unexpected. It may provide an insight into deficits in AAI use. Incorrect assumptions behind inappropriately elevated self-efficacy could be a consequence of the lack of AAI training monitoring and feedback and suggests that it is difficult to identify one's own errors and assess one's own competence. This could have several consequences, not least complacency regarding AAI training and a lack of motivation for continuous practice.
The injection sensing implemented in AllergiSense performed robustly throughout all evaluations presented here. However, in a subsequent qualitative evaluation study in which AllergiSense was provided to expert allergy physicians and nurses, further improvements were identified, for example, the expansion of the training data to include different injection scenarios, such as injecting while lying down. Improved sensing in realistic scenarios could also be useful in prototyping new "smart" AAI designs with emergency AAI sensing capability. Further research in support of anaphylaxis management may have positive implications since people with anaphylaxis and their caregivers are motivated more than most to learn how to use AAIs and carry smartphones because they may need to make emergency calls, and so, the technology platform needed for an assistive healthcare solution is already available.
